Nivolumab treatment for patients who have undergone radical surgery for high-risk muscle-invasive urothelial carcinoma improves their disease-free survival compared with placebo, a study shows.
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Recent advances in cancer management may present challenges for nephrologists.
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Researchers examined causes of avoidable chemotherapy delays as a means of improving the quality of care for outpatients receiving chemotherapy.
Two approaches to downstaging muscle-invasive bladder cancer prior to radical cystectomy include neoadjuvant chemotherapy and transurethral resection.
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
